Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

29
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
29
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence Integration in U.S. Healthcare Professional Degree Programs: A Rapid Scoping Review.

Research square·2026
Same author

Antimicrobial Resistance in Pediatric Infections: Current Status, Challenges, and Future Directions.

Antibiotics (Basel, Switzerland)·2026
Same author

Iron-Based Nanoparticles as Delivery Tools.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Speaking the same language: international cross-validation of emerging biomarkers for juvenile idiopathic arthritis and Still's Disease.

Pediatric rheumatology online journal·2026
Same author

Microbiome-Responsive Hydrogels: From Biological Cues to Smart Biomaterials.

Pharmaceutics·2026
Same author

Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics.

Pharmaceutics·2026

Related Experiment Video

Updated: Feb 20, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.

Keykavous Parang1, Thuy Do1, Clare Dinh1

  • 1Department of Biomedical and Pharmaceutical Sciences, Center for Targeted Drug Delivery, Chapman University School of Pharmacy, Irvine, CA, USA.

Drug Design, Development and Therapy
|February 19, 2026
PubMed
Summary
This summary is machine-generated.

Peptide-drug conjugates (PDCs) offer targeted cancer therapy with enhanced tumor penetration. This review explores PDC design, advantages, challenges, and future directions for improved drug delivery and efficacy.

Keywords:
antibody-drug conjugatecancerdrug deliverylinker chemistrynanotechnologypeptide-drug conjugatetargeting peptidetheranosticstumor penetration

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.9K

Related Experiment Videos

Last Updated: Feb 20, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.9K

Area of Science:

  • Oncology and Pharmaceutical Sciences
  • Drug Delivery Systems
  • Nanomedicine

Background:

  • Peptide-drug conjugates (PDCs) are targeted therapeutics combining homing peptides with cytotoxic payloads.
  • PDCs offer advantages over antibody-drug conjugates (ADCs) due to their smaller size, enabling deeper tumor penetration and faster clearance.
  • Their modular design allows for customization of targeting peptides, linkers, and drug payloads.

Purpose of the Study:

  • To review recent advancements in peptide-drug conjugate (PDC) design and application in cancer therapy.
  • To discuss the mechanisms of tumor delivery and intracellular drug release mediated by PDCs.
  • To highlight current challenges and future directions for PDC development.

Main Methods:

  • Literature review of recent advances in PDC design, mechanisms, and applications.
  • Analysis of key design elements: targeting peptides, linkers, and payloads.
  • Illustrative examples of PDCs in preclinical and clinical settings.

Main Results:

  • PDCs utilize peptide targeting for enhanced drug delivery to tumors, showing superior tissue penetration compared to ADCs.
  • Mechanisms involve receptor binding, endocytosis, and stimuli-responsive linkers for drug release.
  • Examples like ANG1005, lutetium (177Lu)-DOTATATE, and LyP-1-doxorubicin conjugates demonstrate PDC potential.

Conclusions:

  • PDCs present a promising platform for targeted cancer therapy, with ongoing challenges in stability, tumor heterogeneity, and manufacturing.
  • Regulatory hurdles and clinical setbacks, such as with melflufen, highlight the need for further development.
  • Future directions include theranostic PDCs, AI-optimized peptides, and nanomaterial integration for enhanced efficacy.